OncLive TV

Preetesh Jain, MD, PhD, discusses the next steps for a study examining the efficacy of venetoclax in high risk relapsed mantle cell lymphoma.

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

David D. Thiel, MD, chair, discusses the measures that are being taken to protect patients and providers from the coronavirus disease 2019 (COVID-19).

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Hope S. Rugo, MD, discusses the results of the phase 3 KEYNOTE-522 trial in triple-negative breast cancer (TNBC).

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Neehar Parikh, MD, discusses the role of radiation in hepatocellular carcinoma (HCC).

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

Sharyn Lewin, MD, FACS, discusses the impact of the coronavirus disease 2019 (COVID-19) on cancer care.

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Neehar Parikh, MD, discusses the role of radiation in hepatocellular carcinoma (HCC).

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Adam M. Brufsky, MD, PhD, discusses the risk the coronavirus disease 2019 poses to patients with cancer.

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Vivek Subbiah, MD, discusses the utility of tivozanib in renal cell carcinoma.

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Manuel Hidalgo Medina, MD, PhD, discusses some of the exciting research presented at the 2020 ACCR Virtual Annual Meeting I.